375
Views
19
CrossRef citations to date
0
Altmetric
Original Article

Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off

, , , &
Pages 1005-1014 | Accepted 10 May 2005, Published online: 25 May 2005

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (10)

Ryan N. Hansen, Kangho Suh, Michael Serbin, Chuck Yonan & Sean D. Sullivan. (2021) Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. Journal of Medical Economics 24:1, pages 563-569.
Read now
Alexander S. Wang & Steven A. Gunzler. (2019) Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opinion on Pharmacotherapy 20:13, pages 1659-1670.
Read now
Zhan-Miao Yi, Ting-Ting Qiu, Yuan Zhang, Na Liu & Suo-Di Zhai. (2018) Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation. Therapeutics and Clinical Risk Management 14, pages 709-719.
Read now
Carmen Rodríguez-Blázquez, Maria João Forjaz, Luis Lizán, Silvia Paz & Pablo Martínez-Martín. (2015) Estimating the direct and indirect costs associated with Parkinson’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 889-911.
Read now
Jens P Reese, Judith Dams, Yaroslav Winter, Monika Balzer-Geldsetzer, Wolfgang H Oertel & Richard Dodel. (2012) Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. Expert Opinion on Pharmacotherapy 13:7, pages 939-958.
Read now
Heinz Reichmann & Murat Emre. (2012) Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone. Expert Review of Neurotherapeutics 12:2, pages 119-131.
Read now
Ala I Iaconi, Marliese A Zimmerman, Amit S Kulkarni & Rajesh Balkrishnan. (2008) Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature. Expert Opinion on Pharmacotherapy 9:2, pages 163-174.
Read now

Articles from other publishers (9)

Ronald Pfeiffer. 2013. Handbook of Parkinson's Disease, Fifth Edition. Handbook of Parkinson's Disease, Fifth Edition 448 465 .
Robert A Hauser, Ann Hsu, Sherron Kell, Alberto J Espay, Kapil Sethi, Mark Stacy, William Ondo, Martin O'Connell & Suneel Gupta. (2013) Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. The Lancet Neurology 12:4, pages 346-356.
Crossref
Ronald F. Pfeiffer. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease 448 465 .
Judith Dams, Bernhard Bornschein, Jens Peter Reese, Annette Conrads-Frank, Wolfgang H. Oertel, Uwe Siebert & Richard Dodel. (2011) Modelling the Cost Effectiveness of Treatments for Parkinsonʼs Disease. PharmacoEconomics 29:12, pages 1025-1049.
Crossref
James Shearer, Colin Green, Carl E. Counsell & John P. Zajicek. (2011) The Use of Decision-Analytic Models in Parkinsonʼs Disease. Applied Health Economics and Health Policy 9:4, pages 243-258.
Crossref
Ivar Sønbø Kristiansen, Kerstin Bingefors, Dag Nyholm & Dag Isacson. (2012) Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden. Applied Health Economics and Health Policy 7:3, pages 167-180.
Crossref
Dyfrig A. Hughes, Lesley Tilson & Michael Drummond. (2009) Estimating Drug Costs in Economic Evaluations in Ireland and the UK. PharmacoEconomics 27:8, pages 635-643.
Crossref
David A Gallagher & Anette Schrag. (2008) Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease. CNS Drugs 22:7, pages 563-586.
Crossref
Johan SamantaRobert A Hauser. (2006) Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease. Aging Health 2:2, pages 209-219.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.